Synopsis Clozapine, an antipsychotic agent of the dibenzodiazepine class, is characterised
by relatively weak central dopaminergic activity and displays atypical pharmacological and …

The care of people with schizophrenia that has failed to respond to conventional
antipsychotic medication remains a formidable challenge. However, the introduction of …

Clozapine is the best treatment option in several clinical circumstances, including treatment-
resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia …

Clozapine was first manufactured in China in 1976. Clozapine is currently used not only for
treatment-refractory schizophrenia (TRS), but also continues to be used in the treatment of …

The pharmacotherapy of schizophrenia remains an ongoing challenge for researchers and
clinicians alike. Current medications remain suboptimal to effectively treat this illness despite …

Although clozapine is the only antipsychotic agent to have demonstrated superior efficacy in
treatment-refractory schizophrenia, one-to two-thirds of patients do not respond adequately …

Schizophrenia is a debilitating mental disease affecting approximately 1% of the population
worldwide. Since the discovery of the first modern treatment for schizophrenia …

The aim of this study was to use the CYP1A2-null mouse to investigate the in-vivo
contribution of CYP1A2 to clozapine pharmacokinetics and pharmacodynamics. An …

Clozapine is a distinctive antipsychotic agent, having a unique clinical profile and an
idiosyncratic safety profile. More so than with other agents, the weighting of its adverse event …

Neurocognition and clinical symptomatology were evaluated in 27 patients with
schizophrenia during a double-blind, placebo-controlled, crossover study involving …